These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Infliximab in Takayasu arteritis: a safe alternative?
    Author: Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN.
    Journal: Clin Rheumatol; 2007 Jun; 26(6):984-7. PubMed ID: 16633710.
    Abstract:
    OBJECTIVE: To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-alpha, in the treatment of Takayasu arteritis. MATERIALS AND METHODS: We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with Takayasu arteritis. RESULTS: Three out of four patients responded to infliximab treatment, while two of them retained the response during a two-year follow up. A higher dose regimen (5 mg/kg), however, was eventually warranted for two of the responders. No major side effects were noted. CONCLUSIONS: Infliximab might be an effective and safe alternative for patients with Takayasu arteritis.
    [Abstract] [Full Text] [Related] [New Search]